Department of Anesthesiology, Intensive Care and Pain Treatment, Faculty of Medicine of University Maribor, Maribor, Slovenia.
Center for Algology & Pain Management, University Hospitals Leuven, Leuven, Belgium.
Eur J Pain. 2021 May;25(5):969-985. doi: 10.1002/ejp.1744. Epub 2021 Mar 2.
Opioid use for chronic non-cancer pain (CNCP) is under debate. In the absence of pan-European guidance on this issue, a position paper was commissioned by the European Pain Federation (EFIC).
The clinical practice recommendations were developed by eight scientific societies and one patient self-help organization under the coordination of EFIC. A systematic literature search in MEDLINE (up until January 2020) was performed. Two categories of guidance are given: Evidence-based recommendations (supported by evidence from systematic reviews of randomized controlled trials or of observational studies) and Good Clinical Practice (GCP) statements (supported either by indirect evidence or by case-series, case-control studies and clinical experience). The GRADE system was applied to move from evidence to recommendations. The recommendations and GCP statements were developed by a multiprofessional task force (including nursing, service users, physicians, physiotherapy and psychology) and formal multistep procedures to reach a set of consensus recommendations. The clinical practice recommendations were reviewed by five external reviewers from North America and Europe and were also posted for public comment.
The European Clinical Practice Recommendations give guidance for combination with other medications, the management of frequent (e.g. nausea, constipation) and rare (e.g. hyperalgesia) side effects, for special clinical populations (e.g. children and adolescents, pregnancy) and for special situations (e.g. liver cirrhosis).
If a trial with opioids for chronic noncancer pain is conducted, detailed knowledge and experience are needed to adapt the opioid treatment to a special patient group and/or clinical situation and to manage side effects effectively.
If a trial with opioids for chronic noncancer pain is conducted, detailed knowledge and experience are needed to adapt the opioid treatment to a special patient group and/or clinical situation and to manage side effects effectively. A collaboration of medical specialties and of all health care professionals is needed for some special populations and clinical situations.
阿片类药物治疗慢性非癌性疼痛(CNCP)存在争议。由于缺乏泛欧对此问题的指导意见,欧洲疼痛联合会(EFIC)委托撰写了一份立场文件。
临床实践建议由 EFIC 协调的八个科学协会和一个患者自助组织制定。在 MEDLINE 中进行了系统的文献检索(截至 2020 年 1 月)。给出了两类指导意见:基于证据的建议(基于随机对照试验或观察性研究的系统评价证据支持)和良好临床实践(GCP)声明(基于间接证据或病例系列、病例对照研究和临床经验支持)。应用 GRADE 系统从证据到建议。建议和 GCP 声明由多专业工作组(包括护理、服务使用者、医生、物理治疗和心理学)制定,并通过正式的多步骤程序制定一套共识建议。临床实践建议由来自北美和欧洲的五名外部评论员进行了审查,并在网上公开征求意见。
欧洲临床实践建议为联合其他药物治疗、管理常见(如恶心、便秘)和罕见(如痛觉过敏)副作用、特殊临床人群(如儿童和青少年、妊娠)和特殊情况(如肝硬化)提供了指导。
如果进行了慢性非癌性疼痛的阿片类药物试验,需要详细的知识和经验来调整阿片类药物治疗以适应特殊患者群体和/或临床情况,并有效管理副作用。
如果进行了慢性非癌性疼痛的阿片类药物试验,需要详细的知识和经验来调整阿片类药物治疗以适应特殊患者群体和/或临床情况,并有效管理副作用。对于一些特殊人群和临床情况,需要医学专业和所有医疗保健专业人员的合作。